BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar...
Brain
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic...
Q2 2024 Revenue and Business Highlights, Guidance Upgrade
MELBOURNE, Australia, July 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update...
Brainomix and Boehringer Ingelheim Launch Strategic Partnership in Fibrosing Lung Disease
The project will evaluate the real-world impact of Brainomix's e-Lung imaging software to improve the identification and access to treatment for...
BioWorld by Clarivate Celebrates Nine Wins at 2024 APEX Awards
Recognized for excellence in writing, news, mental health, financial/investment and economics categories LONDON, July 18, 2024 /PRNewswire/ -- BioWorld™ published...
AI-Based Medical Diagnostic Tools Market Set to Exceed USD 11.5 Billion by 2034: Global Surge in AI Start-up Funding Expands Diagnostic Systems Integration | TMR
AI-powered diagnostic systems deliver precise and efficient diagnoses, enabling healthcare professionals to develop timely and effective treatment plans. This integration...
Cumulus Neuroscience to Present Data at AAIC 2024 Annual Meeting and Technology and Dementia Preconference
Full analysis of first-in-class CNS-101 study measuring functional neurophysiology at home in patients living with mild Alzheimer's dementiaPoster presentations scheduled for the...
Hyperfine Announces FDA Clearance of Software Update That Enables Faster Acquisition of Best-in-Class Ultra-Low-Field Brain Images
The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list.GUILFORD,...
Hyperfine Announces FDA Clearance of Software Update That Enables Faster Acquisition of Best-in-Class Ultra-Low-Field Brain Images
The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list.GUILFORD,...
CervoMed to Participate in the Emerging Growth Conference
BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for...
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progressionROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) --...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had...
NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum
The Column Group (TCG) led the round with participation from a select group of investorsPrimary sclerosing cholangitis (PSC) is a...
ONWARD® Medical Publishes Annual Sustainability Summary
Company strengthens sustainability practices prior to commercializationEINDHOVEN, the Netherlands, July 17, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD),...
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION17 JULY 2024 at 8.30 EEST Inside information: Phase III ARANOTE...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p <...
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients...
Subtle Medical Receives FDA-Clearance for Industry First AI-powered Synthetic Imaging Software, SubtleSYNTH™
Subtle Medical's new software is now available for clinical use in the US, further redefining the speed and quality of...
Positrigo Receives FDA Clearance for Breakthrough Brain PET System
After several years of development, the company's first dedicated brain PET system comes to market in the US. ZURICH, July...